Intrexon (NYSE:XON) had its price target increased by Stifel Nicolaus from $39.00 to $57.00 in a report issued on Friday, November 10th, MarketBeat Ratings reports. Stifel Nicolaus currently has a buy rating on the biotechnology company’s stock.
Several other research analysts have also issued reports on XON. Zacks Investment Research lowered shares of Intrexon from a hold rating to a sell rating in a research note on Thursday, July 13th. BidaskClub lowered shares of Intrexon from a hold rating to a sell rating in a research note on Friday, August 4th. Northland Securities set a $30.00 price target on shares of Intrexon and gave the stock a buy rating in a research note on Monday, August 7th. JMP Securities reiterated an outperform rating and issued a $42.00 price target on shares of Intrexon in a research note on Thursday, October 5th. Finally, Griffin Securities reiterated a buy rating and issued a $55.00 price target on shares of Intrexon in a research note on Friday, October 6th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. Intrexon presently has a consensus rating of Hold and a consensus price target of $38.50.
Shares of Intrexon (XON) traded up $0.60 during trading on Friday, hitting $13.54. 1,463,000 shares of the company traded hands, compared to its average volume of 1,140,025. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.05 and a quick ratio of 1.85. Intrexon has a 52 week low of $10.26 and a 52 week high of $30.96.
COPYRIGHT VIOLATION NOTICE: This news story was posted by BBNS and is owned by of BBNS. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US & international trademark and copyright law. The legal version of this news story can be accessed at https://baseballnewssource.com/markets/stifel-nicolaus-raises-intrexon-corporation-xon-price-target-to-57-00/1774417.html.
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.
Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with our FREE daily email newsletter.